NCT03742115

Etoposide in the First-line Treatment of Adult EBV-HLH

A Randomized Controlled Trial of Etoposide in the First-line Treatment of Adult Epstein-barr Virus Associated Hemophagocytic Lymphohistiocytosis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

his study aimed to investigate the efficacy of etoposide as the first line therapy for adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Conditions

• Hemophagocytic Lymphohistiocytosis

Interventions

Type	Name	Description
DRUG	Etoposide	150 mg/m2 twice weekly for 2 weeks and then weekly
DRUG	Dexamethasone	initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
DRUG	Etoposide	150 mg/m2 weekly
DRUG	IVIG	0.5 g/kg, once every 4 weeks

Timeline

• Start date: 2018-12-01
• Primary completion: 2019-12-01
• Completion: 2020-12-01
• First posted: 2018-11-15
• Last updated: 2018-11-15

Locations

1 site across 1 country: China